Table 3. Patient and tumour characteristics in interval melanomas and cases of the pre-SCREEN era.
|
Interval melanomas |
Melanomas 1999–2002 |
|||||
|---|---|---|---|---|---|---|
| Women (n=169) | Men (n=89) | Total (n=258) | Women (n=1832) | Men (n=1443) | Total (n=3275) | |
| Mean age, years (s.d.) | 50.2 (16.2) | 64.2 (14.6) | 55.1 (17.0) | 55.6 (18.4) | 57.9 (15.7) | 56.6 (17.3) |
|
Age group | ||||||
| 20–34 years | 31 (18.3%) | 5 (5.6%) | 36 (14.0%) | 284 (15.5%) | 142 (9.8%) | 426 (13.0%) |
| 35–49 years | 60 (35.5%) | 8 (9.0%) | 68 (26.4%) | 438 (23.9%) | 278 (19.3%) | 716 (21.9%) |
| 50–64 years | 38 (22.5%) | 22 (24.7%) | 60 (23.3%) | 480 (26.2%) | 495 (34.3%) | 975 (29.8%) |
| ⩾65 years | 40 (23.7%) | 54 (60.7%) | 94 (36.4%) | 630 (34.4%) | 528 (36.6%) | 1158 (35.4%) |
|
Risk factors | ||||||
| No risk factor for CM | 95 (56.2%) | 57 (64.0%) | 152 (58.9%) | N/A | N/A | N/A |
| Any risk factor for CM | 74 (43.8%) | 32 (36.0%) | 106 (41.1%) | N/A | N/A | N/A |
| Family history (first-degree) of CM | 4 (2.4%) | 1 (1.1%) | 5 (1.9%) | N/A | N/A | N/A |
| Multiple common nevi | 49 (29.0%) | 20 (22.5%) | 69 (26.7%) | N/A | N/A | N/A |
| Clinically atypical nevi | 48 (28.4%) | 22 (24.7%) | 70 (27.1%) | N/A | N/A | N/A |
| Congenital moles | 13 (7.7%) | 3 (3.4%) | 16 (6.2%) | N/A | N/A | N/A |
|
Histological type | ||||||
| Nodular melanoma (8721/3a) | 12 (7.1%) | 5 (5.6%) | 17 (6.6%) | 149 (8.1%) | 130 (9.0%) | 279 (8.5%) |
| Lentigo maligna melanoma (8742/2 & 8742/3a) | 18 (10.7%) | 15 (16.9%) | 33 (12.8%) | 157 (8.6%) | 116 (8.0%) | 273 (8.3%) |
| Superficial spreading melanoma (8743/2 & 8743/3a) | 47 (27.8%) | 27 (30.3%) | 74 (28.7%) | 536 (29.3%) | 421 (29.2%) | 957 (29.2%) |
| Acral lentiginous melanoma (8744/3a) | 0 (0.0%) | 1 (1.1%) | 1 (0.4%) | 19 (1.0%) | 10 (0.7%) | 29 (0.9%) |
| Melanoma, NOS (8720/2 & 8720/3a) | 84 (49.7%) | 38 (42.7%) | 122 (47.3%) | 891 (48.6%) | 687 (47.6%) | 1578 (48.2%) |
| Others | 8 (4.7%) | 3 (3.4%) | 11 (4.3%) | 80 (4.4%) | 79 (5.5%) | 159 (4.9%) |
|
Tumour size | ||||||
| In situ melanoma | 82 (48.5%) | 26 (29.2%) | 108 (41.9%) | 448 (24.5%) | 288 (20.0%) | 736 (22.5%) |
| T1 | 45 (26.6%) | 26 (29.2%) | 71 (27.5%) | 408 (22.3%) | 325 (22.5%) | 733 (22.4%) |
| T2 | 8 (4.7%) | 7 (7.9%) | 15 (5.8%) | 204 (11.1%) | 163 (11.3%) | 367 (11.2%) |
| T3 | 2 (1.2%) | 3 (3.4%) | 5 (1.9%) | 129 (7.0%) | 124 (8.6%) | 253 (7.7%) |
| T4 | 2 (1.2%) | 3 (3.4%) | 5 (1.9%) | 64 (3.5%) | 46 (3.2%) | 110 (3.4%) |
| Tx | 30 (17.8%) | 24 (27.0%) | 54 (20.9%) | 579 (31.6%) | 497 (34.4%) | 1076 (32.9%) |
|
Anatomic siteb | ||||||
| Lip | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (0.2%) | 2 (0.1%) | 6 (0.2%) |
| Eyelid, including canthus | 3 (1.8%) | 3 (3.4%) | 6 (2.3%) | 13 (0.7%) | 5 (0.3%) | 18 (0.6%) |
| Ear and external auricular canal | 0 (0.0%) | 3 (3.4%) | 3 (1.2%) | 15 (0.8%) | 19 (1.3%) | 34 (1.0%) |
| Other and unspecified parts of face | 17 (10.1%) | 18 (20.2%) | 35 (13.6%) | 193 (10.5%) | 155 (10.7%) | 348 (10.6%) |
| Scalp and neck | 2 (1.2%) | 3 (3.4%) | 5 (1.9%) | 36 (2.0%) | 88 (6.1%) | 124 (3.8%) |
| Trunk | 35 (20.7%) | 27 (30.3%) | 62 (24.0%) | 371 (20.3%) | 590 (40.9%) | 961 (29.3%) |
| Upper limb, including shoulder | 35 (20.7%) | 16 (18.0%) | 51 (19.8%) | 364 (19.9%) | 194 (13.4%) | 558 (17.0%) |
| Lower limb, including hip | 67 (39.6%) | 13 (14.6%) | 80 (31.0%) | 677 (37.0%) | 212 (14.7%) | 889 (27.2%) |
| Other sites/overlapping | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) | 2 (0.1%) |
| Unspecified | 10 (5.9%) | 6 (6.7%) | 16 (6.2%) | 158 (8.6%) | 177 (12.3%) | 335 (10.2%) |
Abbreviations: CM=cutaneous melanoma; N/A=not available; NOS=not otherwise specified.
a
Codes according to the International Classification of Diseases for Oncology, 3rd revision (ICD-O-3).
b
According to the fourth character of the International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10).